INTRODUCTION AND OBJECTIVES: Stereotactic Body Radiation Therapy (SBRT) remains an emerging treatment option for men with prostate adenocarcinoma. Retrospective analyses utilizing Medicare claims data provided caution regarding potentially higher rates of cystitits and urethrtitis. This study reports the 7-year freedom from grade 2þ bladder toxicity (Cystitis and Urethritis) as it relates to normal tissue dosimetry in a large patient cohort.
METHODS: Between April 2, 2010 and August 25, 2017, 963 patients with prostate cancer were treated with definitive robotic-based SBRT. Based on NCCN risk categories, 29.9%, 57.1% and 13.0% had low, intermediate, and high risk disease, respectively. 17.8% received concurrent Androgen Deprivation Therapy (ADT). The median prescription dose was 3500cGy (3500-3625) delivered in 5 fractions. The median age was 66 years (41-92) and the mean CTV and PTV sizes were 82.4 cc's (20.5-238.8) and 134.6 cc's (45.1-331.2). Longterm bladder toxicity was characterized as occurring ! 6 months post-radiation and scored by RTOG late toxicity scale. Freedom from grade 2þ bladder toxicity was assessed using the Kaplan-Meier method and analyzed using Cox regression methods.
RESULTS: 5 patients developed grade 2 bladder toxicity and 7 developed grade 3. Toxicity manifested: 8.3% (year 1), 50% (year 1-2), and 41.7% (year 3). 1 case occurred over 6.5 years after treatment. With a mean follow-up of 24 months (6-137), the 7-year freedom from ! grade 2 and ! grade 3 bladder toxicity was 96% and 96.9%, respectively. Mean Bladder V3000cGy and V3300cGy volumes were not significantly higher in patients with ! grade 2 toxicity (16.2% vs. 15.0%, respectively). The mean Bladder V3700cGy was 1.52cc's and mean Bladder maximum dose was 3863.4cGy. There was no statistical difference in bladder dosimetric paramaters between those with ! grade 2 toxicity and those without. Age, race, anticoagulation use, histologic grade, and ADT did not predict for !grade 2 bladder toxicity in this cohort.
CONCLUSIONS: SBRT for prostate cancer is well tolerated with a low actuarial risk of grade 2þ cystitis or urethritis. In patients treated with robotic intrafraction translation/rotation correction and with rigid dose constraints employed, rates appear lower than those cited by retrospective claims series. With long-term follow-up, most cases of grade 2þ bladder toxicity occur within the first three years post SBRT delivery. (2) cycles. Prospective collection of diagnostic information age, PSA, DRE findings, clinical stage, WHO Modified Gleason scores, co-morbidities, treatment duration, and clavien-dindo systemt 30-day outcomes was performed using Focalyx App (ISO, Android). Patients undergoing focal hemiablation or wholegland treatment were excluded. Only patients with fusion target lesions were eligible.
RESULTS: 83 patients underwent MR Fusion Target Cryoablation for clinically localized prostate cancer. Of these, 35 accrued in Miami, 17 in New York, and 31 in Boston performed under local anesthesia. Procedure execution was consistent across institutions: all performed under 60 minutes. All procedures were completed. mean and median pain scores was 2 (range 0-5). 30-day adverse events were observed in 10 patients, of these: Grade I: 1 referring symptoms consistent with UTI; 2 developed orchitis, 2 perineal hematomas, 3 patients had urinary retention requiring catheters over 7 days but less than 14 days and 1 patient urethral syndrome -frequency and dysuria without retention that lasted 2 weeks. One patient experienced a Grade IIIa adverse event as urinary retention did not improve after 3 weeks and required hospital admission and transurethral resection of the prostate and recovered uneventfully. There were no anesthesia related complications after these procedures. At 3 months PSA levels and average flow rates experienced median delta changes of -3.7 nd/ml (35% decline) and 4.9 cc/s (63% improvement), respectively CONCLUSIONS: This report presents multi-institutional safety data of a novel protocol evaluating men managed with Office based MRI/US fusion target cryoablation. Major adverse events occurred in one patient. The absence of regional or general anesthesia added to the safety profile
